GlaxoSmithKline – media

Senators Write to GlaxoSmithKline to Boost Shingrix Supply

As a result of the high demand for GlaxoSmithKline's new shingles vaccine, Shingrix, two U.S. senators have urged the pharma giant to boost inventory levels on facing a shortage in the supplies even after the company established their "fair and equitable" process to ship Shingrix doses.
- Source: FiercePharma
- 818
- July 10, 2018
Company Insight GlaxoSmithKline shingles Shingrix vaccine
GSK pharma boss Miels rejigs commercial operations to stoke new launches Trelegy, Shingrix

GlaxoSmithKline's new CEO Emma Walmsley isn’t the only one shaking things up at the top of the British drugmaker.
- Source: fiercepharma.
- 706
- March 23, 2018
Company Insights GlaxoSmithKline Shingrixin vaccine
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal

In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
- Source: pharmalive
- 560
- March 20, 2018
Akcea-TTR-LRx GlaxoSmithKline Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.